The 2009 H1N1 swine flu vaccine would become accessible in one’s neighbourhood quicker than what majority of individuals might have anticipated.
With almost everyone having a bevy of queries, here’s a useful guide to clear many a miasma.
When could the H1N1 swine flu vaccine become available?
In some locations, the vaccine will be obtainable even as early as 2nd October, with several states providing the vaccine starting the week of 5th October. In this opening week, an entirety of six to seven million vaccine dosages would have been spun out by the assemblage lines of 5 vaccine producers and would be circulated. Nearly half of those preliminary dosages would be flu injections; and about 3.4 million would be the FluMist nasal spray vaccination.
On what priority basis would the H1N1 swine flu vaccine be administered?
The FluMist nasal spray vaccination is permitted solely for healthy individuals in the age band of 2-49 years. The initial vaccine doses would be given to the health care employees that would be having direct contact with the patients, to the care providers and family members of below six months infants as small babies are highly prone to contracting flu leading to complications. However, infants only above six months can be given the nasal spray vaccine. The nasal spray vaccine is also not advisable during pregnancy.
However, the flu injections, dependent on the producer, are permitted for children that are six months of age and also deemed safe during pregnancy.
Who would get the initial doses of the H1N1 vaccine?
There are 5 categories that have been selected to be the initial ones to get the vaccine:
- As pregnancy raises a woman’s likelihood of acute flu six fold, hence expectant women would be given top precedence.
- Domestic members and care providers of infants lesser than six months of age. This would additionally include those working at day care centres. Infants are too small to be given vaccination and are more likely to contract severe flu.
- As the younger age bracket is noted to be the most commonly affected by the H1N1 swine flu, hence those lying in the age group of six months to twenty-four years have been given first preference.
- Health care employees and emergency medical staff.
- Adults in the ages 25-64 having a medical condition like asthma, which raises the chances of complications due to flu.
- The sparse initial doses of the H1N1 swine flu vaccine are intended to be restrictively given to sub-sets like toddlers below four years of age.
However, suppliers might probably not be too stringent, perceiving it better to promptly use the vaccine than to let it remain seated in the cooling racks.
Would there be adequate vaccine if one is not at the front of the queue?
The initial six to seven million doses is just the beginning. The CDC has stated that by 12th October there would be nearly forty million vaccine dosages that would have been dispatched. Subsequently, on a week-by-week basis there would be an expected shipment of twenty million dosages.
On the whole, the United States has bought 251 million dosages of the H1N1 swine flu vaccine. The United States has also contributed ten percent of the supply to countries that are unable to meet the expenses of buying the vaccine. This would leave 226 million dosages for the United States.
As grown-ups would require merely 1 dose and kids would require two doses, and as not all would opt to go in for vaccination, this would translate to all that want the vaccine, would get it sooner or later.
What is the safety quotient of the H1N1 swine flu vaccine?
The H1N1 swine flu vaccine (injections and nasal sprays) are manufactured in analogous manner just as the seasonal swine flu vaccine.
On a roughly annual basis, the seasonal vaccine – that comprises of a constituent derived from the seasonal H1N1 virus – is amended to resemble a flu virus that has modified its genetic constitution. This similar form of tuning has lead to the formation of the H1N1 swine flu vaccine.
Hence, it has received the stamp of approval from the FDA as they regarded it as a mere strain modification and not a new-fangled vaccine.
Despite that, there are on-going long and short-lasting clinical trials. The outcome of the short –term trials show that except for the normal tenderness and perchance reddening at the jab site, the vaccines have no serious side effects.
The H1N1 swine flu vaccine just alike the seasonal flu vaccine is not suitable for all. The vaccine is made in the hen’s eggs, hence those having allergic reaction to egg might not be able to take it.
This is also no perceivable likelihood of long-lasting side effects, though the CDC is leaving no stone unturned in this regard. The CDC and the vaccine producers have upped their security examination process to watch out for anything dubious in persons that received vaccination against the new flu.
How safe is the H1N1 swine flu vaccine?
With millions slated to receive the vaccine, probability of something dire occurring around the same time they get the vaccine is bound to happen, for which the vaccine cannot be held accountable.
But, in a hypothetical setup if a woman were to suffer miscarriage soon following a vaccination? There would be daunting media reporting and the CDC would probe into the matter. However, public health specialists are cautioning individuals to comprehend that episodes like miscarriages are not unusual; and more time would be needed to understand if this is more frequent among women that underwent vaccination as compared to women that didn’t get vaccinated.
Who must go in for the H1N1 swine flu vaccination?
As it is a novel virus to which human exposure is a first time occurrence, hence all are susceptible to the H1N1 swine flu due to which all could gain from the vaccine.
Though citing among elderly persons past 65 years has till now been an atypical occurrence. However, there have been some adults past the age of 24 years in good health that have ailed severe consequences of swine flu. These sets of people are requested to wait till others have got the opportunity to get the vaccine.